Testing tezepelumab for kids with severe asthma
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 5 and 11 years old.
- Your child has been diagnosed with severe asthma for at least 6 months.
- Your child has been on daily asthma controller medicine for at least 3 months, with the same dose for the past month.
- Your child has had at least 2 severe asthma attacks in the last year, or 1 attack that required a hospital stay.
- Your child weighs at least 16 kg (about 35 pounds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational biologic medicine called QL2302, which is given as an injection, to see if it works as well as a similar approved medicine (Tezspire) for people with severe asthma. If you qualify, you would receive either QL2302 or Tezspire, and the study will track how well your asthma is controlled and your lung function over time.
This study tests a medicine called tezepelumab (an injection) for people with severe asthma who also have a chronic cough. It may help reduce asthma attacks and improve cough symptoms.
This trial tests a medication called tezepelumab to see if it can improve symptoms for people with chronic sinusitis and nasal polyps who also have severe asthma. It may help reduce inflammation and improve breathing and nasal symptoms.
This study tests a new medicine called tozorakimab for adults whose asthma is not well controlled despite using their usual inhalers. It aims to see if it can reduce asthma attacks and improve symptoms.
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.